Next Article in Journal
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
Previous Article in Journal
WWOX Possesses N-Terminal Cell Surface-Exposed Epitopes WWOX7-21 and WWOX7-11 for Signaling Cancer Growth Suppression and Prevention In Vivo
Previous Article in Special Issue
The Role and Function of microRNA in the Pathogenesis of Multiple Myeloma
Open AccessReview

Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma

Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(11), 1819; https://doi.org/10.3390/cancers11111819
Received: 5 October 2019 / Revised: 16 November 2019 / Accepted: 17 November 2019 / Published: 19 November 2019
(This article belongs to the Special Issue Latest Development in Multiple Myeloma)
Reactivation of hepatitis B virus (HBV) is a well-known complication in patients with hematological malignancies during or after cytotoxic chemotherapy. If the initiation of antiviral therapy is delayed in patients with HBV reactivation, these patients can develop severe hepatitis and may die of fulminant hepatitis. The preventive strategy for HBV reactivation in patients with malignant lymphoma has already been established based on some prospective studies. As there was an increased number of novel agents being approved for the treatment of multiple myeloma (MM), the number of reported cases of HBV reactivation among MM patients has gradually increased. We conducted a Japanese nationwide retrospective study and revealed that HBV reactivation in MM patients is not rare and that autologous stem cell transplantation is a significant risk factor. In this study, around 20% of all patients with HBV reactivation developed HBV reactivation after 2 years from the initiation of therapy, unlike malignant lymphoma. This might be due to the fact that almost all of the patients received chemotherapy for a long duration. Therefore, a new strategy for the prevention of HBV reactivation in MM patients is required. View Full-Text
Keywords: hepatitis B virus; reactivation; multiple myeloma; novel agents; autologous stem cell transplantation hepatitis B virus; reactivation; multiple myeloma; novel agents; autologous stem cell transplantation
MDPI and ACS Style

Tsukune, Y.; Sasaki, M.; Komatsu, N. Reactivation of Hepatitis B Virus in Patients with Multiple Myeloma. Cancers 2019, 11, 1819.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop